Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study

Objectives. This open-label trial assessed the efficacy and safety of rifaximin as first-line therapy in hospitalized patients with Clostridium difficile-associated diarrhea (CDAD). Methods. We enrolled thirteen patients who had a confirmed diagnosis of CDAD characterized by ≥3 unformed stools/day a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, David T., Sohi, Sunana, Glathar, Matthew, Thomas, Tojo, Yadron, Nicole, Surma, Bonnie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216319/
https://www.ncbi.nlm.nih.gov/pubmed/22114587
http://dx.doi.org/10.1155/2011/106978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216319/
https://www.ncbi.nlm.nih.gov/pubmed/22114587
http://dx.doi.org/10.1155/2011/106978

Ejemplares similares